Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(147 produtos)
- Bcr-Abl(103 produtos)
- EGFR(572 produtos)
- FAK(71 produtos)
- FLT(91 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(88 produtos)
- Src(80 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(267 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1483 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GSK2646264
CAS:<p>GSK2646264 (Compound 44) inhibits SYK (pIC50=7.1) and kinases like LCK, LRRK2; penetrates skin.</p>Fórmula:C24H26N2O2Cor e Forma:SolidPeso molecular:374.48JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Fórmula:C26H30N6OPureza:98%Cor e Forma:SolidPeso molecular:442.56Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Fórmula:C22H20N6O3Cor e Forma:SolidPeso molecular:416.43BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Cor e Forma:SolidPeso molecular:487.94FGFR-IN-8
CAS:<p>FGFR-IN-8, potent oral FGFR inhibitor for wild-type/mutant types, induces apoptosis with anti-cancer properties.</p>Fórmula:C27H31Cl2N9O2Cor e Forma:SolidPeso molecular:584.5Famitinib malate
CAS:<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Fórmula:C27H33FN4O7Cor e Forma:SolidPeso molecular:544.57UNC5293
CAS:<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Fórmula:C30H42N6O2Cor e Forma:SolidPeso molecular:518.69EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Fórmula:C32H28BrF3N6O4SCor e Forma:SolidPeso molecular:729.57Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Fórmula:C20H17N9Pureza:98%Cor e Forma:SolidPeso molecular:383.41Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Fórmula:C21H33F3N6O11Pureza:98%Cor e Forma:SolidPeso molecular:602.521(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Cor e Forma:SolidPeso molecular:438.43ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Fórmula:C27H34ClN7O3SCor e Forma:SolidPeso molecular:572.12BT424
CAS:BT424, a specific HCK inhibitor, modulates macrophage activation and autophagy in vitro, and mitigates inflammation and renal fibrosis in the UUO model [1].Fórmula:C22H15BCl2N2O2Pureza:98%Cor e Forma:SolidPeso molecular:421.08HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Fórmula:C24H28N6O3Pureza:98%Cor e Forma:SolidPeso molecular:448.52EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Fórmula:C36H46BrN8O2PCor e Forma:SolidPeso molecular:733.68FLT3/ITD-IN-5
CAS:FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.Fórmula:C23H25N7O2Cor e Forma:SolidPeso molecular:431.49HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Fórmula:C16H8F5NO4SPureza:97.99%Cor e Forma:SolidPeso molecular:405.3ALK/ROS1-IN-1
CAS:<p>ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).</p>Fórmula:C30H35F3N6O3Pureza:98%Cor e Forma:SolidPeso molecular:584.63JAK-IN-4
CAS:<p>JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.</p>Fórmula:C18H21N4Na2O6PPureza:98%Cor e Forma:SolidPeso molecular:466.341JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Fórmula:C19H17N5O4Pureza:98%Cor e Forma:SolidPeso molecular:379.37DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:547.56CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Fórmula:C22H25BrF5N5O5SPureza:98%Cor e Forma:SolidPeso molecular:646.43PI3K/VEGFR2-IN-1
CAS:<p>PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.</p>Fórmula:C17H14ClN3OSPureza:98%Cor e Forma:SolidPeso molecular:343.83BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OCor e Forma:SolidPeso molecular:433.33Sulfatinib
CAS:<p>Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to</p>Fórmula:C24H28N6O3SPureza:99.21% - >99.99%Cor e Forma:SolidPeso molecular:480.58MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Fórmula:C29H23F3N4O2Pureza:98%Cor e Forma:SolidPeso molecular:516.51TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Fórmula:C17H21FN6OPureza:98%Cor e Forma:SolidPeso molecular:344.39Atiprimod dimaleate
CAS:Atiprimod Dimaleate is a JAK2 inhibitor.Fórmula:C30H52N2O8Cor e Forma:SolidPeso molecular:568.74BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Fórmula:C16H12BrN5Cor e Forma:SolidPeso molecular:354.2MS 154
CAS:<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Fórmula:C46H54ClFN8O8Cor e Forma:SolidPeso molecular:901.42Ruxolitinib sulfate
CAS:<p>Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.</p>Fórmula:C17H20N6O4SCor e Forma:SolidPeso molecular:404.45JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Fórmula:C20H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:380.44FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Fórmula:C25H26N6O2Pureza:98%Cor e Forma:SolidPeso molecular:442.523EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Cor e Forma:SolidPeso molecular:538.64HDAC-IN-63
CAS:<p>HDAC-IN-63 (Compound 63) is a dual FLT3/HDAC inhibitor with IC50 values of 0.844 nM for FLT3 and 30.0 nM for HDAC1.</p>Fórmula:C25H26Cl2N6O3Cor e Forma:SolidPeso molecular:529.42Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Fórmula:C28H32F2N6O5Pureza:99.08% - 99.38%Cor e Forma:SolidPeso molecular:570.59CHMFL-FLT3-122
CAS:<p>CHMFL-FLT3-122 is a potent and orally available FLT3 kinase inhibitor used to treat FLT3-ITD positive acute myeloid leukemia.</p>Fórmula:C26H29N7O2Pureza:99.63%Cor e Forma:SolidPeso molecular:471.55Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Pureza:95%Cor e Forma:LiquidALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Fórmula:C26H29ClD3N5O3SPureza:98%Cor e Forma:SolidPeso molecular:533.1TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Fórmula:C17H11ClF2N4O2Cor e Forma:SolidPeso molecular:376.74Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Fórmula:C10H18O4Pureza:≥98%Cor e Forma:SolidPeso molecular:202.25ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Fórmula:C27H34ClN7O3SPureza:98%Cor e Forma:SolidPeso molecular:572.12Nazartinib S-enantiomer
CAS:<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Fórmula:C26H31ClN6O2Pureza:98%Cor e Forma:SolidPeso molecular:495.02YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Fórmula:C30H30N4O3Pureza:98%Cor e Forma:SolidPeso molecular:494.58AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Fórmula:C22H29N7O5Pureza:98%Cor e Forma:SolidPeso molecular:471.52Nezulcitinib
CAS:<p>Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.</p>Fórmula:C30H37N7O2Cor e Forma:SolidPeso molecular:527.66BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Cor e Forma:SolidPeso molecular:662.78KB SRC 4
CAS:KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4Fórmula:C32H23ClN8Pureza:98.83% - 99.34%Cor e Forma:SolidPeso molecular:555.03HER2-IN-5
CAS:<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Fórmula:C27H33N7O3Cor e Forma:SolidPeso molecular:503.6TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Fórmula:C26H17F4N5O4Cor e Forma:SolidPeso molecular:539.44
